Shares of Mednax, Inc (NYSE:MD) have earned an average rating of “Hold” from the fifteen brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and one has assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $64.50.
A number of research firms have issued reports on MD. Jefferies Group LLC reissued a “hold” rating on shares of Mednax in a report on Monday, April 10th. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Thursday, April 13th. Bank of America Corporation downgraded shares of Mednax from a “buy” rating to an “underperform” rating in a report on Thursday, May 4th. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Finally, Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $55.00 to $68.00 in a report on Thursday, June 22nd.
Mednax (MD) traded up 1.19% during midday trading on Monday, hitting $57.61. 721,405 shares of the company traded hands. The company has a market capitalization of $5.32 billion, a price-to-earnings ratio of 17.20 and a beta of 0.44. Mednax has a 12-month low of $53.80 and a 12-month high of $76.04. The stock’s 50-day moving average price is $57.74 and its 200 day moving average price is $63.76.
Mednax (NYSE:MD) last announced its quarterly earnings results on Thursday, May 4th. The company reported $0.75 EPS for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.01. The business had revenue of $835.60 million for the quarter, compared to analyst estimates of $837.01 million. Mednax had a net margin of 9.54% and a return on equity of 12.81%. Mednax’s quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.87 EPS. On average, equities analysts forecast that Mednax will post $3.58 EPS for the current year.
In other news, Director Manuel Kadre purchased 21,704 shares of the business’s stock in a transaction dated Friday, May 5th. The stock was bought at an average price of $55.79 per share, with a total value of $1,210,866.16. Following the acquisition, the director now owns 111,255 shares in the company, valued at approximately $6,206,916.45. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph M. Calabro sold 23,327 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the sale, the insider now directly owns 296,379 shares of the company’s stock, valued at approximately $16,300,845. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,074 shares of company stock valued at $1,830,508. 2.40% of the stock is currently owned by insiders.
Several hedge funds have recently modified their holdings of the company. PNC Financial Services Group Inc. increased its stake in shares of Mednax by 0.5% in the first quarter. PNC Financial Services Group Inc. now owns 9,099 shares of the company’s stock worth $632,000 after buying an additional 47 shares during the period. Pacer Advisors Inc. increased its stake in shares of Mednax by 3.2% in the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock worth $125,000 after buying an additional 55 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Mednax by 5.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,604 shares of the company’s stock worth $106,000 after buying an additional 77 shares during the period. Morgan Dempsey Capital Management LLC increased its stake in shares of Mednax by 3.6% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock worth $157,000 after buying an additional 78 shares during the period. Finally, Bronfman E.L. Rothschild L.P. increased its stake in shares of Mednax by 3.0% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,122 shares of the company’s stock worth $217,000 after buying an additional 92 shares during the period.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/07/20/mednax-inc-md-receives-64-50-average-price-target-from-analysts.html.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.
